PMID- 36808888
OWN - NLM
STAT- MEDLINE
DCOM- 20230224
LR  - 20230321
IS  - 2001-1326 (Electronic)
IS  - 2001-1326 (Linking)
VI  - 13
IP  - 2
DP  - 2023 Feb
TI  - Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel 
      population in the tumour microenvironment and immunotherapy target.
PG  - e1199
LID - 10.1002/ctm2.1199 [doi]
LID - e1199
AB  - BACKGROUND: Dendritic cells (DCs) mediate divergent immune effects by activating 
      T cells or negatively regulating the immune response to promote immune tolerance. 
      They perform specific functions determined by their tissue distribution and 
      maturation state. Traditionally, immature and semimature DCs were described to 
      have immunosuppressive effects, leading to immune tolerance. Nonetheless, recent 
      research has demonstrated that mature DCs can also suppress the immune response 
      under certain circumstances. MAIN BODY: Mature DCs enriched in immunoregulatory 
      molecules (mregDCs) have emerged as a regulatory module across species and tumour 
      types. Indeed, the distinct roles of mregDCs in tumour immunotherapy have sparked 
      the interest of researchers in the field of single-cell omics. In particular, 
      these regulatory cells were found to be associated with a positive response to 
      immunotherapy and a favourable prognosis. CONCLUSION: Here, we provide a general 
      overview of the latest and most notable advances and recent findings regarding 
      the basic features and complex roles of mregDCs in nonmalignant diseases and the 
      tumour microenvironment. We also emphasise the important clinical implications of 
      mregDCs in tumours.
CI  - (c) 2023 The Authors. Clinical and Translational Medicine published by John Wiley & 
      Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
FAU - Li, Jiaxin
AU  - Li J
AD  - Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University, 
      Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, 
      Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Department of Breast Surgery, Affiliated Hangzhou First People's Hospital, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Huang, Huanhuan
AU  - Huang H
AD  - Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University, 
      Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, 
      Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Jiang, Jiahuan
AU  - Jiang J
AD  - Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University, 
      Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, 
      Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Department of Radiotherapy, Second Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, China.
FAU - Ni, Chao
AU  - Ni C
AUID- ORCID: 0000-0002-2724-8896
AD  - Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University, 
      Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, 
      Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
LA  - eng
GR  - LR19H160001/Natural Science Foundation of Zhejiang Province/
GR  - LY21H100004/Natural Science Foundation of Zhejiang Province/
GR  - 81773065/Natural Science Foundation of China/
GR  - 81800024/Natural Science Foundation of China/
GR  - 81502463/Natural Science Foundation of China/
GR  - 82173089/Natural Science Foundation of China/
GR  - 2019R01007/Leading Innovative and Entrepreneur Team Introduction Program of 
      Zhejiang/
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Transl Med
JT  - Clinical and translational medicine
JID - 101597971
SB  - IM
MH  - Humans
MH  - *Dendritic Cells
MH  - Tumor Microenvironment
MH  - Immunotherapy
MH  - *Neoplasms/pathology
MH  - Immunity
PMC - PMC9937888
OTO - NOTNLM
OT  - dendritic cells
OT  - tumour antigen-presentation
OT  - tumour immune microenvironment
OT  - tumour immunology
OT  - vaccination
COIS- The authors declare no conflicts of interest.
EDAT- 2023/02/23 06:00
MHDA- 2023/02/25 06:00
PMCR- 2023/02/17
CRDT- 2023/02/22 13:23
PHST- 2023/01/21 00:00 [revised]
PHST- 2022/10/17 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/02/23 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2023/02/22 13:23 [entrez]
PHST- 2023/02/17 00:00 [pmc-release]
AID - CTM21199 [pii]
AID - 10.1002/ctm2.1199 [doi]
PST - ppublish
SO  - Clin Transl Med. 2023 Feb;13(2):e1199. doi: 10.1002/ctm2.1199.